Purpose: To investigate the co-existence of diabetic retinopathy (DR) and age-related macular degeneration (AMD), based on five-year data in a University setting.
Methods: Participants in the study included 1739 patients with diabetes mellitus, who were examined in our setting from 2015 to 2019. The presence of DR and AMD was recorded while the clinical characteristics of patients were evaluated.
Results: In our study sample, 183 out of 1739 patients with diabetes mellitus (10.5%) were diagnosed with AMD, 116 without any sign of DR, and 67 with DR. In the group of patients with DR, dry AMD was noticed mostly in patients with mild non-proliferative DR (NPDR) (11.5% dry AMD) compared to those with moderate NPDR (4.5% dry AMD), severe NPDR (4.2%) and proliferative DR (PDR) (2.4%). Similar results were found for neovascular AMD (3% in mild NPDR, 1.9% in moderate NPDR, 1% in severe NPDR, and 1.8% in PDR). There was a significant correlation between the co-existence of both diseases and the severity of DR, with AMD being less prevalent in patients with more severe DR. In patients with diabetic macular edema, dry AMD was observed in 12 (4.6%) and neovascular AMD in nine (3.4%).
Conclusions: The five-year prevalence of AMD in DR patients was 9% while in diabetic patients without DR it was found to be 11.5%. Therefore, the co-existence of DR and AMD is not common, suggesting that DR may be protective for AMD development.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720086 | PMC |
http://dx.doi.org/10.7759/cureus.31051 | DOI Listing |
Hereditas
December 2024
Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, No. 1, Dongjiaomin Lane, Dongcheng District, Beijing, 100730, China.
Background: Age-related macular degeneration (AMD) is the leading cause of visual impairment in the elderly population. Accumulating evidence has revealed the possible association between metabolites and AMD. This study aimed to assess the effect of plasma metabolites on AMD and its two subtypes using a bidirectional two-sample Mendelian randomization approach.
View Article and Find Full Text PDFJ Fr Ophtalmol
December 2024
Department of Ophthalmology, Faculty of Medicine, Kastamonu University, Kastamonu, Turkey; Department of Ophthalmology, Kastamonu Training and Research Hospital, Kastamonu, Turkey.
Purpose: To evaluate the natural history of dry age-related macular degeneration (AMD) through advanced retinal pigment epithelium (RPE) analysis and sub-RPE illumination (SRI) data and to elucidate their correlation with disease progression.
Methods: A total of 82 patients with dry AMD were included in this longitudinal study. Spectral-domain optical coherence tomography (SD-OCT) was utilized to evaluate central macular thickness (CMT), central retinal thickness (CRT), foveal outer nuclear layer (ONL) thickness, and ellipsoid zone (EZ) integrity.
Int J Mol Sci
December 2024
Department of Drug Sciences, Section of Pharmacology, University of Pavia, 27100 Pavia, Italy.
Age-related macular degeneration (AMD) is the most common cause of irreversible loss of central vision in elderly subjects, affecting men and women equally. It is a degenerative pathology that causes progressive damage to the macula, the central and most vital part of the retina. There are two forms of AMD depending on how the macula is damaged, dry AMD and wet or neovascular AMD.
View Article and Find Full Text PDFImmun Inflamm Dis
December 2024
Tongji University School of Medicine, Shanghai Tenth People's Hospital, Shanghai, China.
Background: Age-related macular degeneration (AMD) is a major cause of irreversible visual impairment, with dry AMD being the most prevalent form. Programmed cell death of retinal pigment epithelium (RPE) cells is a central mechanism in the pathogenesis of dry AMD. Ferroptosis, a recently identified form of programmed cell death, is characterized by iron accumulation-induced lipid peroxidation.
View Article and Find Full Text PDFProg Retin Eye Res
December 2024
Department of Ophthalmology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark.
Anti-vascular endothelial growth factor (VEGF) therapies have revolutionized the treatment of neovascular age-related macular degeneration (nAMD) and other retinal diseases. However, the necessity for repeated intravitreal injections and the observation of variable treatment responses calls for new treatment modalities where fewer and more effective interventions can result in a clinical effect. Gene therapy might be such an alternative, and therefore the development and clinical application of gene therapy aimed at modifying gene expression has received considerable attention.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!